Top-Thema

20.01.18
ROUNDUP 2: US-​Bundesregierung wegen Haushaltssperre im Zwangsstillstand

New Study Published in Lancet Respiratory Medicine Highlights QIAGEN's QuantiFERON-TB Potential to Predict Active Tuberculosis Risk in Infants

Donnerstag, 16.02.2017 08:25 von PR Newswire

PR Newswire

HILDEN, Germany and GERMANTOWN, Maryland, February 16, 2017 /PRNewswire/ --

Results Suggest Benefits of Quantitative Screening of Young Children in Countries With High TB Burden 

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that data published in The Lancet Respiratory Medicine journal shows screening with QuantiFERON-TB Gold (QFT) can detect latent tuberculosis (TB) infection in otherwise healthy young children and can predict which are likely to progress to the active stage of this life-threatening respiratory disease.

     (Photo: http://mma.prnewswire.com/media/468908/QuantiFERON_TB_Blood_Test.jpg )

Results from the study of more than 2,500 young children in South Africa suggest that screening with the modern QuantiFERON-TB blood test could save lives in countries with a high TB burden by identifying those children most at risk of developing active disease. The study noted young children are particularly vulnerable to TB, with up to 20% of those infected by the bacteria developing the active TB disease.

"This study marks a true milestone. For the first time, there is a test that has demonstrated the potential to quantify the risk for young children to develop active tuberculosis. Researchers found that those with a QuantiFERON-TB test result above a certain threshold were far more likely than others to get sick with the active disease. TB is a terrible killer of children in high-burden countries, so early diagnosis and treatment could save many lives," said Dr. Masae Kawamura, Senior Director, TB Medical and Scientific Affairs, at QIAGEN.

Click here for full press release:

https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID={049783C5-174E-41FE-974D-1662A6DBD416}&lang=en

Contacts:

QIAGEN

Investor Relations
John Gilardi
+49-2103-29-11711
e-mail: ir@QIAGEN.com

Public Relations
Dr. Thomas Theuringer
+49-2103-29-11826
e-mail: pr@QIAGEN.com

SOURCE QIAGEN N.V.